drug-related adverse reaction leading to caspofungin discontinuation was The printed package leaflet of the medicinal product must state the name and. CANCIDAS® is a sterile, lyophilised product for intravenous infusion that contains a Interpretive standards (or breakpoints) for caspofungin against Candida. CANCIDAS* is a sterile, lyophilized product for intravenous (IV) infusion that CANCIDAS is the first of a new class of antifungal drugs (glucan synthesis.
|Published (Last):||26 July 2010|
|PDF File Size:||9.79 Mb|
|ePub File Size:||7.62 Mb|
|Price:||Free* [*Free Regsitration Required]|
When valve replacement or hardware removal is not possible, chronic suppressive therapy with fluconazole is recommended after initial treatment. There is no clinical experience in those with severe hepatic impairment Child-Pugh score more than 9, class C.
Limited safety data suggest that an increase in dose to 70 mg daily is well tolerated. Caspofungin is administered by slow insedt infusion.
Clinically significant elevations in caspofungin plasma concentrations have been noted in patients with moderate hepatic impairment i. Growth of Candida sp.
Caspofungin acetate (Cancidas ®) – GlobalRPH
Studies to evaluate the effects of exposure on a breast-fed infant have not been conducted; however, based on caspofungin’s poor oral absorption, the risks appear to be low.
Patients with hepatic disease, or those with cholestasis, hepatitis or jaundice may require a dose adjustment of caspofungin. We do not record any personal information entered above. Administering inducers of hepatic cytochrome P, such as ethotoin, concurrently with caspofungin may reduce the plasma concentrations of caspofungin.
Mechanism of Action Caspofungin acetate, an echinocandin, is an antifungal agent. Aspergillus fumigatus Aspergillus flavus Aspergillus terreus Candida albicans Candida glabrata Candida guilliermondii Candida krusei Candida parapsilosis Candida tropicalis.
Caspofungin vials are single use only; discard any unused reconstituted solution. Reconstituted caspofungin in the vial may be stored at 25 degrees C or less 77 degrees F or less for 1 hour prior to dilution. A mg loading dose has not been studied with this indication. The risk of relapse is greater in HIV-infected patients for esophageal candidiasis, and suppressive antifungal therapy may be considered after a course of treatment.
Cancidass does not interact substantially with the cytochrome P enzyme system, but does undergo significant hepatic metabolism. Oral antifungal agents e. For the treatment of Aspergillus cardiovascular system infections in patients who are refractory to or intolerant of other antifungal therapies.
Cancidas (caspofungin acetate) dose, indications, adverse effects, interactions from
Recipient’s Email Separate multiple email address with a comma Please enter valid email address Recipient’s email is required. Important Safety Information Caspofungin is contraindicated in patients with known hypersensitivity to any component of this product.
Caspofungin is contraindicated in patients with known hypersensitivity to any component of this product. IV echinocandin antifungal Used for aspergillosis, candidemia, esophageal candidiasis, and empiric treatment in febrile neutropenia Fever and infusion-related reactions common.
Caspofungin Acetate for Injection Now Available from Fresenius Kabi
Visually inspect prepared infusions for particulate matter and discoloration prior to administration. Beta 1,3 -D-glucan is not present in mammalian cells and therefore is an attractive target for antifungal activity. Please review the latest applicable package insert for additional information and possible updates.
However, site of infection, local susceptibility patterns, and specific microbial susceptibility should be assessed before choosing an alternative agent. Monitor patients who develop abnormal liver function tests LFTs during concomitant use with Caspofungin. If a breast-feeding infant experiences an adverse effect related to a maternally ingested or administered cancisas, health care providers are encouraged to report the adverse effect to the FDA.
Because of the risk of relapse of oropharyngeal candidiasis in patients with HIV infections, suppressive oral therapy could be considered [see see package insert Clinical Studies For empirical therapy for presumed fungal infection in patients with febrile neutropenia. It is not known how caspofungin drug clearance is induced. Currently, there are no established interpretive breakpoints for Aspergillus sp.
These mutations are associated with higher MICs and breakthrough infection. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a inserh for clinical judgment.
Hydrolysis results in two tyrosine amino acid by-products that are rapidly cleared by the kidneys. Treatment for at least 14 days and for at least 7 days after neutropenia and symptoms resolve is recommended for patients found to have a fungal infection.
National Institutes of Health, U. Consider intravascular catheter removal.
Embryotoxic effects have been observed at doses in animals that produced exposure similar to those seen in humans treated with a 70 mg dose. Reference s National Institutes of Health, U. Invasive Aspergillosis A single mg loading dose should be administered on Day 1, followed by 50 mg daily thereafter. Please see the full prescribing information for Caspofungin Acetate for Injection, including packabe warning, at http: Send the page ” ” to a friend, relative, colleague or yourself.